---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-065459"
form_type: "8-K"
ticker: "BBIO"
cik: "0001743881"
company_name: "BridgeBio Pharma, Inc."
filed_at: "2023-03-09T23:59:59+00:00"
generated_at: "2026-06-18T07:17:07.795635+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# BridgeBio Pharma prices $150M public offering of common stock at $17.00/share

## Summary
- Offering of 8,823,530 shares (plus underwriters' 30-day option for 1,323,529 shares) at $17.00/share.
- Gross proceeds ~$150M; net proceeds ~$143.1M after underwriting discounts and expenses.
- Expected use of proceeds: fund clinical/pre-clinical development, research, working capital, and potential acquisitions.
- Expected closing on or around March 10, 2023.
- Goldman Sachs, Evercore, Morgan Stanley, and KKR Capital Markets are book-running managers.

## SEC filing metadata
- accession: 0001193125-23-065459
- form_type: 8-K
- ticker: BBIO
- cik: 0001743881
- company_name: BridgeBio Pharma, Inc.
- filed_at: 2023-03-09T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1743881/000119312523065459/0001193125-23-065459-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1743881/000119312523065459/d463641d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-065459
- JSON: https://secwatch.observer/filing/0001193125-23-065459.json
- Plain text: https://secwatch.observer/filing/0001193125-23-065459.txt

## Key facts
- Material Agreements
  BridgeBio Pharma, Inc. entered into Underwriting Agreement with Goldman Sachs & Co. LLC, Evercore Group L.L.C. and Morgan Stanley & Co. LLC valued at $17.00 per share (effective 2023-03-07).
  - Action: entry
  - Agreement: underwriting
  - Counterparty: Goldman Sachs & Co. LLC, Evercore Group L.L.C. and Morgan Stanley & Co. LLC
  - Value: $17.00 per share
  - Effective: 2023-03-07
  source text: On March 7, 2023, BridgeBio Pharma, Inc. (the “Company”) entered into an Underwriting Agreement (the “Underwriting Agreement”) with Goldman Sachs & Co. LLC, Evercore Group L.L.C. and Morgan Stanley & Co. LLC, as representatives of the several underwriters listed on Schedule I thereto (collectively, the “Underwriters”), relating to an underwritten public offering (the “Offering”) of 8,823,530 shares of the Company’s common stock, $0.001 par value per share (the “Common Stock”), at a price to the public of $17.00 per share.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1743881/000119312523065459/0001193125-23-065459-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.